TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00817804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the V60 Mask Ventilator
Description: The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the V60 Mask Ventilator
Description: The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
Study: NCT03331029

Intervention type: DEVICE
Group type: OTHER
Intervention: transesophageal investigation
Description: Comparison of 3D ultrasound with transesophageal echocardiography
Study: NCT01803230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine supplementation
Description: creatine supplementation
Study: NCT00413634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anagrelide hydrochloride
Description: Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anagrelide hydrochloride
Description: Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
Study: NCT03690284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Double Lumen Tube
Description: Patient will be intubated with Mallinckrodt Double Lumen endotracheal tube for single lung ventilation during thoracic surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight Double Lumen Tube
Description: Patient will be intubated with the VivaSight double lumen endotracheal tube with an integrated camera for single lung ventilation during thoracic surgery
Study: NCT00729885

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Goggle with 20 degree error
Description: The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized Goggle
Description: The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
Study: NCT00917631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Co-bedding (caring for twins in the same incubator)
Description: Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes).
Study: NCT01031186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO
Study: NCT03229096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib plus XELOX
Description: three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks.
Study: NCT02429752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
Study: NCT00530049

Intervention type: OTHER
Intervention: questionnaire administration

Intervention type: PROCEDURE
Intervention: assessment of therapy complications

Intervention type: PROCEDURE
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Study: NCT03732950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00988897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXALIPLATIN (SR96669)
Description: Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL (5-FU)
Description: Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEUCOVORIN (LV)
Description: Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
Study: NCT01322594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI2338
Description: MEDI2338 single intravenous (IV) dose (lowest dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI2338
Description: MEDI2338 single IV dose (next highest dose)
Study: NCT01625377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
Study: NCT01322594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI2338
Description: MEDI2338 single IV dose (next highest dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI2338
Description: MEDI2338 single IV dose (next highest dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI2338
Description: MEDI2338 single IV dose (highest dose)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single IV dose
Study: NCT02792114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesothelin-targeted T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Study: NCT01222754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 1. With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.~2. Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT, 54-59.4 Gy
Description: Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
Study: NCT03016481

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: the Community Health Worker -Personalized Support for Progress
Description: Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual- Social Worker
Description: Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
Study: NCT03074435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indoor residual sprayings
Description: Houses will be spayed with this formulation containing Pyrimiphos methyl.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Larvicide
Description: Larval breeding sites will be treated with larvicide

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivermectin
Study: NCT00783315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Call-Center Directed (CCD) Weight Loss Program
Description: This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Directed (IPD) Weight Loss Program
Description: This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed Weight Loss Program
Description: Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
Study: NCT00895128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
Study: NCT00950040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Description: The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health education
Description: The intervention will consist of information about several general health behaviors.
Study: NCT03467217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan potassium
Description: Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo losartan capsule
Description: Matching placebo losartan oral capsule
Study: NCT00988897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEVACIZUMAB
Description: Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
Study: NCT04236622

Intervention type: OTHER
Intervention: Periodontal clinical exam
Description: The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis.

Intervention type: OTHER
Intervention: Periodontal clinical exam
Description: The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis.
Study: NCT03041701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
Study: NCT04505722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered at a single dose of 5\*10\^10 virus particles (vp) on Day 1 (or Month 6 for placebo recipients) and as a single booster dose at Year 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered at a single dose of 5\*10\^10 virus particles (vp) on Day 1 (or Month 6 for placebo recipients) and as a single booster dose at Year 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo.
Study: NCT02275780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doravirine
Description: Doravirine 100 mg tablet administered p.o. q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg tablet administered p.o. q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Darunavir 800 mg tablet administered p.o. q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir 100 mg tablet administered p.o. q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRUVADA™ or EPZICOM™/KIVEXA™
Description: The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA™ or EPZICOM™/KIVEXA™
Description: The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
Study: NCT01619137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: water and soap
Description: water and soap for 6-8 hours per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine And normal salin treatment
Description: use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
Study: NCT02379351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Home Non-Stress Test Device
Description: Airstrip® Sense4Baby™
Study: NCT02441270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Study: NCT01393509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
Study: NCT01984892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments.
Study: NCT03041701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Twice daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
Study: NCT01625377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid
Description: Dose of 1440 mg/day from transplantation to month 6 post- transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid
Description: Dose of 1440 mg/day from transplantation to month 6 post- transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
Study: NCT04392089

Intervention type: DEVICE
Intervention: Masimo, LidCO
Description: * Near-infrared spectroscopy (NIRS), pulse oxymetry (saturation), continous hemoglobine, peripheral perfusion index (PPI) as measured with Massimo~* Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), stroke volume (SV), heart rate (HR), cardiac output (CO), systemic vascular resistance (SVR) as measured with LiDCO
Study: NCT03581474

Intervention type: DEVICE
Group type: OTHER
Intervention: Bronchoscopic procedure
Description: Single-use flexible bronchoscope aScope 3 Large
Study: NCT01626820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: 1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: 1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
Study: NCT04032873

Intervention type: OTHER
Group type: OTHER
Intervention: Monetary Cost of Immobilization Treatments
Description: Information regarding the monetary cost of casting and splinting patient's buckle fracture to be presented to adult subject/payer.

Intervention type: OTHER
Group type: OTHER
Intervention: Monetary Cost of Immobilization Treatments
Description: Information regarding the monetary cost of casting and splinting patient's buckle fracture to be presented to adult subject/payer.

Intervention type: OTHER
Group type: OTHER
Intervention: Physician
Description: The monetary cost information is relayed by the patient's physician

Intervention type: OTHER
Group type: OTHER
Intervention: Study Team
Description: The monetary cost information is relayed by a member of the study team

Intervention type: OTHER
Group type: OTHER
Intervention: Before Initial Treatment Decision
Description: Monetary cost information is relayed during the initial consult, before the treatment decision is made.